NKGen Biotech (NYSE:NKGN) (NYSE:NKGN) is a clinical‐stage biotechnology company dedicated to the development of novel natural killer (NK) cell‐based immunotherapies for oncology and infectious diseases. Leveraging an off‐the‐shelf NK cell platform, the company engineers NK cells to enhance cytotoxic activity against tumor and pathogen targets while maintaining a favorable safety profile. NKGen’s research focuses on next‐generation cell therapy candidates designed to address unmet needs in hematologic malignancies and solid tumors.
The company’s lead product candidates are built on its proprietary NK‐92 cell line technology, which simplifies manufacturing and enables scalable production of ready‐to‐use cell therapies. In preclinical studies, these engineered NK cells have demonstrated potent anti‐tumor efficacy, improved persistence in the tumor microenvironment, and reduced risk of cytokine release syndrome. NKGen’s pipeline also includes exploratory programs aimed at leveraging its platform in viral infection models, positioning the company to expand into broader immunotherapy applications.
Founded in 2019 by a team of immunology and cell therapy experts, NKGen Biotech maintains research and development operations in the United States and Asia, with strategic collaborations that span North America, Europe, and the Asia‐Pacific region. The company’s state‐of‐the‐art manufacturing facility supports GMP‐compliant production and scale‐up efforts. By combining academic innovation with industry partnerships, NKGen has rapidly advanced its therapeutic candidates toward clinical evaluation.
NKGen Biotech is led by an experienced management team headed by Chief Executive Officer Dr. James Lee, whose prior roles include leadership positions at leading cell therapy companies. The executive team also includes Chief Scientific Officer Dr. Anna Park, who brings extensive expertise in NK cell biology, and Chief Financial Officer Michael Chen, responsible for guiding the company through its public listing and capital markets activities. Under their leadership, NKGen aims to bring safe, effective, and commercially viable NK cell therapies to patients worldwide.
